{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:58:56Z","timestamp":1771952336562,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06768-w","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T06:39:14Z","timestamp":1770619154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term real-world thrombotic and clinical outcomes in polycythemia vera \u2013 a hospital-based i2b2 cohort study"],"prefix":"10.1007","volume":"105","author":[{"given":"Natalie","family":"Neumark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna Aleksandra","family":"Jalowiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Tichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Porret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linet","family":"Njue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Vrotniakaite-Bajerciene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Prince-Eladnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Angelillo-Scherrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Rov\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"6768_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0035-6","author":"S Cerquozzi","year":"2017","unstructured":"Cerquozzi S, Barraco D, Lasho T et al (2017) Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-017-0035-6","journal-title":"Blood Cancer J"},{"key":"6768_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6768_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"6768_CR4","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1182\/blood.2019001318","volume":"134","author":"BL Stein","year":"2019","unstructured":"Stein BL, Martin K (2019) From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Blood 134:1902\u20131911. https:\/\/doi.org\/10.1182\/blood.2019001318","journal-title":"Blood"},{"key":"6768_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"key":"6768_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06466-z","author":"V De Stefano","year":"2025","unstructured":"De Stefano V, Passamonti F, Palandri F et al (2025) Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-025-06466-z","journal-title":"Ann Hematol"},{"key":"6768_CR7","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1200\/JCO.2015.61.6474","volume":"33","author":"BL Stein","year":"2015","unstructured":"Stein BL, Oh ST, Berenzon D et al (2015) Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol 33:3953\u20133960. https:\/\/doi.org\/10.1200\/JCO.2015.61.6474","journal-title":"J Clin Oncol"},{"key":"6768_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ajh.25303","volume":"94","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Barbui T (2019) Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 94:133\u2013143. https:\/\/doi.org\/10.1002\/ajh.25303","journal-title":"Am J Hematol"},{"key":"6768_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"key":"6768_CR10","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M et al (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9:e301\u2013e311. https:\/\/doi.org\/10.1016\/S2352-3026(22)00046-1","journal-title":"Lancet Haematol"},{"key":"6768_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/ejh.12707","volume":"97","author":"R Mesa","year":"2016","unstructured":"Mesa R, Verstovsek S, Kiladjian J-J et al (2016) Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol 97:192\u2013200. https:\/\/doi.org\/10.1111\/ejh.12707","journal-title":"Eur J Haematol"},{"key":"6768_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123393","volume":"11","author":"KA Jalowiec","year":"2022","unstructured":"Jalowiec KA, Vrotniakaite-Bajerciene K, Jalowiec J et al (2022) JAK2 unmutated polycythaemia-real-world data of 10 years from a tertiary reference hospital. J Clin Med 11:3393. https:\/\/doi.org\/10.3390\/jcm11123393","journal-title":"J Clin Med"},{"key":"6768_CR13","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790. https:\/\/doi.org\/10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"key":"6768_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143706","volume":"15","author":"F Palandri","year":"2023","unstructured":"Palandri F, Rossi E, Auteri G et al (2023) Predictors of response to hydroxyurea and switch to ruxolitinib in HU-resistant polycythaemia VERA patients: a real-world PV-NET study. Cancers (Basel) 15:3706. https:\/\/doi.org\/10.3390\/cancers15143706","journal-title":"Cancers (Basel)"},{"key":"6768_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/ejh.14124","volume":"112","author":"A Theocharides","year":"2024","unstructured":"Theocharides A, Gisslinger H, De Stefano V et al (2024) Ruxolitinib in patients with polycythemia vera resistant and\/or intolerant to hydroxyurea: European observational study. Eur J Haematol 112:379\u2013391. https:\/\/doi.org\/10.1111\/ejh.14124","journal-title":"Eur J Haematol"},{"key":"6768_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11739-011-0634-3","volume":"7","author":"R Landolfi","year":"2012","unstructured":"Landolfi R, Di Gennaro L, Nicolazzi MA et al (2012) Polycythemia vera: gender-related phenotypic differences. Intern Emerg Med 7:509\u2013515. https:\/\/doi.org\/10.1007\/s11739-011-0634-3","journal-title":"Intern Emerg Med"},{"key":"6768_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3324\/haematol.2010.031070","volume":"96","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Finazzi G et al (2010) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96:315. https:\/\/doi.org\/10.3324\/haematol.2010.031070","journal-title":"Haematologica"},{"key":"6768_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12185-016-2105-0","volume":"105","author":"AM Yesilova","year":"2017","unstructured":"Yesilova AM, Yavuzer S, Yavuzer H et al (2017) Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. Int J Hematol 105:70\u201378. https:\/\/doi.org\/10.1007\/s12185-016-2105-0","journal-title":"Int J Hematol"},{"key":"6768_CR19","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41375-025-02646-y","volume":"39","author":"F Palandri","year":"2025","unstructured":"Palandri F, Breccia M, Elli EM et al (2025) Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea. Leukemia 39:1928\u20131936. https:\/\/doi.org\/10.1038\/s41375-025-02646-y","journal-title":"Leukemia"},{"key":"6768_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/s-2007-996124","volume":"23","author":"R Landolfi","year":"1997","unstructured":"Landolfi R, Marchioli R (1997) European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Semin Thromb Hemost 23:473\u2013478. https:\/\/doi.org\/10.1055\/s-2007-996124","journal-title":"Semin Thromb Hemost"},{"key":"6768_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/794240","volume":"2011","author":"R Marchioli","year":"2011","unstructured":"Marchioli R, Finazzi G, Specchia G et al (2011) The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis 2011:794240. https:\/\/doi.org\/10.1155\/2011\/794240","journal-title":"Thrombosis"},{"key":"6768_CR22","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1002\/ajh.24583","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Carobbio A et al (2017) The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol 92:E5\u2013E6. https:\/\/doi.org\/10.1002\/ajh.24583","journal-title":"Am J Hematol"},{"key":"6768_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/ejh.13291","volume":"103","author":"C van de Ree-Pellikaan","year":"2019","unstructured":"van de Ree-Pellikaan C, de Kreuk A, Schaar CG et al (2019) Treatment strategies for polycythemia vera: observations in a Dutch \u201creal-world\u201d cohort study. Eur J Haematol 103:453\u2013459. https:\/\/doi.org\/10.1111\/ejh.13291","journal-title":"Eur J Haematol"},{"key":"6768_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s12185-020-02887-w","volume":"112","author":"N Komatsu","year":"2020","unstructured":"Komatsu N, Jun G, Yonezu T, Ohashi Y (2020) Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. Int J Hematol 112:176\u2013184. https:\/\/doi.org\/10.1007\/s12185-020-02887-w","journal-title":"Int J Hematol"},{"key":"6768_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11239-019-02029-y","volume":"49","author":"FS Seguro","year":"2020","unstructured":"Seguro FS, Teixeira LLC, da Rosa LI et al (2020) Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. J Thromb Thrombolysis 49:667\u2013672. https:\/\/doi.org\/10.1007\/s11239-019-02029-y","journal-title":"J Thromb Thrombolysis"},{"key":"6768_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/VHRM.S429995","volume":"19","author":"G Benevolo","year":"2023","unstructured":"Benevolo G, Marchetti M, Melchio R et al (2023) Diagnosis and management of cardiovascular risk in patients with polycythemia vera. Vasc Health Risk Manag 19:765\u2013778. https:\/\/doi.org\/10.2147\/VHRM.S429995","journal-title":"Vasc Health Risk Manag"},{"key":"6768_CR27","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1111\/bjh.19337","volume":"204","author":"A Enblom-Larsson","year":"2024","unstructured":"Enblom-Larsson A, Renlund H, Andr\u00e9asson B et al (2024) Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera-a matched nationwide population-based study. Br J Haematol 204:1740\u20131751. https:\/\/doi.org\/10.1111\/bjh.19337","journal-title":"Br J Haematol"},{"key":"6768_CR28","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E et al (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124:3021\u20133023. https:\/\/doi.org\/10.1182\/blood-2014-07-591610","journal-title":"Blood"},{"key":"6768_CR29","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20132232. https:\/\/doi.org\/10.1200\/JCO.2005.07.062","journal-title":"J Clin Oncol"},{"key":"6768_CR30","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00277-022-04963-z","volume":"101","author":"A Triguero","year":"2022","unstructured":"Triguero A, Pedraza A, P\u00e9rez-Encinas M et al (2022) Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Ann Hematol 101:2231\u20132239. https:\/\/doi.org\/10.1007\/s00277-022-04963-z","journal-title":"Ann Hematol"},{"key":"6768_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00960-1","volume":"13","author":"T Barbui","year":"2023","unstructured":"Barbui T, Carobbio A, Thiele J et al (2023) The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients. Blood Cancer J 13:187. https:\/\/doi.org\/10.1038\/s41408-023-00960-1","journal-title":"Blood Cancer J"},{"key":"6768_CR32","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2006","unstructured":"Landolfi R, Di Gennaro L, Barbui T et al (2006) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446\u20132452. https:\/\/doi.org\/10.1182\/blood-2006-08-042515","journal-title":"Blood"},{"key":"6768_CR33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","volume":"98","author":"M Griesshammer","year":"2019","unstructured":"Griesshammer M, Kiladjian J-J, Besses C (2019) Thromboembolic events in polycythemia vera. Ann Hematol 98:1071\u20131082. https:\/\/doi.org\/10.1007\/s00277-019-03625-x","journal-title":"Ann Hematol"},{"key":"6768_CR34","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","volume":"3","author":"A Carobbio","year":"2019","unstructured":"Carobbio A, Ferrari A, Masciulli A et al (2019) Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 3:1729\u20131737. https:\/\/doi.org\/10.1182\/bloodadvances.2019000211","journal-title":"Blood Adv"},{"key":"6768_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.beha.2005.07.011","volume":"19","author":"R Landolfi","year":"2006","unstructured":"Landolfi R, Cipriani MC, Novarese L (2006) Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 19:617\u2013633. https:\/\/doi.org\/10.1016\/j.beha.2005.07.011","journal-title":"Best Pract Res Clin Haematol"},{"key":"6768_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1207395","volume":"11","author":"RH Bekendam","year":"2023","unstructured":"Bekendam RH, Ravid K (2023) Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms. Front Cell Dev Biol 11:1207395. https:\/\/doi.org\/10.3389\/fcell.2023.1207395","journal-title":"Front Cell Dev Biol"},{"key":"6768_CR37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1160\/TH15-04-0326","volume":"115","author":"V De Stefano","year":"2016","unstructured":"De Stefano V, Qi X, Betti S, Rossi E (2016) Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost 115:240\u2013249. https:\/\/doi.org\/10.1160\/TH15-04-0326","journal-title":"Thromb Haemost"},{"key":"6768_CR38","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","volume":"111","author":"J-J Kiladjian","year":"2008","unstructured":"Kiladjian J-J, Cervantes F, Leebeek FWG et al (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111:4922\u20134929. https:\/\/doi.org\/10.1182\/blood-2007-11-125328","journal-title":"Blood"},{"key":"6768_CR39","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3324\/haematol.2021.279032","volume":"107","author":"JI Zwicker","year":"2021","unstructured":"Zwicker JI, Paranagama D, Lessen DS et al (2021) Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. Haematologica 107:1106\u20131110. https:\/\/doi.org\/10.3324\/haematol.2021.279032","journal-title":"Haematologica"},{"key":"6768_CR40","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3324\/haematol.2019.221234","volume":"104","author":"A Ferrari","year":"2019","unstructured":"Ferrari A, Carobbio A, Masciulli A et al (2019) Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica 104:2391\u20132399. https:\/\/doi.org\/10.3324\/haematol.2019.221234","journal-title":"Haematologica"},{"key":"6768_CR41","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","volume":"107","author":"AI Schafer","year":"2006","unstructured":"Schafer AI (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107:4214\u20134222. https:\/\/doi.org\/10.1182\/blood-2005-08-3526","journal-title":"Blood"},{"key":"6768_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood-2020-137144","volume":"136","author":"BL Stein","year":"2020","unstructured":"Stein BL, Patel K, Scherber RM et al (2020) Mortality and causes of death of patients with polycythemia vera: analysis of the Reveal prospective, observational study. Blood 136:36\u201337. https:\/\/doi.org\/10.1182\/blood-2020-137144","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06768-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06768-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06768-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:04:15Z","timestamp":1771949055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06768-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6768"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06768-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}